kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.
Company profile
Ticker
KNSA
Exchange
Website
CEO
Sanj K. Patel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Kiniksa Pharmaceuticals Corp. • Kiniksa Pharmaceuticals (France) SARL • Kiniksa Pharmaceuticals (Germany) GmbH • Kiniksa Pharmaceuticals GmbH • Kiniksa Pharmaceuticals (UK), Ltd. • Primatope Therapeutics, Inc. ...
KNSA stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
8-K
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23 Apr 24
PRE 14A
Preliminary proxy
10 Apr 24
8-K
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
2 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
8-K
Practice Statement Letter
29 Mar 24
Transcripts
KNSA
Earnings call transcript
2024 Q1
23 Apr 24
KNSA
Earnings call transcript
2023 Q4
28 Feb 24
KNSA
Earnings call transcript
2023 Q3
31 Oct 23
KNSA
Earnings call transcript
2023 Q2
25 Jul 23
KNSA
Earnings call transcript
2023 Q2
25 Jul 23
KNSA
Earnings call transcript
2023 Q1
2 May 23
KNSA
Earnings call transcript
2023 Q1
2 May 23
KNSA
Earnings call transcript
2022 Q4
28 Feb 23
KNSA
Earnings call transcript
2022 Q3
1 Nov 22
KNSA
Earnings call transcript
2022 Q2
5 Aug 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 117.83 mm | 117.83 mm | 117.83 mm | 117.83 mm | 117.83 mm | 117.83 mm |
Cash burn (monthly) | (no burn) | 4.83 mm | 3.64 mm | 1.54 mm | (no burn) | 216.67 k |
Cash used (since last report) | n/a | 32.92 mm | 24.84 mm | 10.48 mm | n/a | 1.48 mm |
Cash remaining | n/a | 84.91 mm | 92.99 mm | 107.35 mm | n/a | 116.35 mm |
Runway (months of cash) | n/a | 17.6 | 25.5 | 69.9 | n/a | 537.0 |
Institutional ownership, Q2 2023
79.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 20 |
Closed positions | 20 |
Increased positions | 49 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 442.58 bn |
Total shares | 31.77 mm |
Total puts | 198.40 k |
Total calls | 219.80 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Rubric Capital Management | 3.38 mm | $47.56 bn |
BLK Blackrock | 3.16 mm | $44.50 bn |
Vanguard | 3.09 mm | $43.47 bn |
Baker Bros. Advisors | 2.81 mm | $39.56 bn |
STT State Street | 1.65 mm | $23.26 bn |
Pictet Asset Management | 1.52 mm | $21.36 bn |
MS Morgan Stanley | 1.31 mm | $18.43 bn |
ArrowMark Colorado | 985.20 k | $13.87 bn |
Fairmount Funds Management | 704.46 k | $9.92 bn |
Hillhouse Capital Advisors | 698.74 k | $9.84 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Eben Tessari | Class A Common Share | Payment of exercise | Dispose F | No | No | 17.9 | 801 | 14.34 k | 126,024 |
8 Apr 24 | Eben Tessari | Class A Common Share | Option exercise | Acquire M | No | No | 0 | 2,726 | 0.00 | 126,825 |
8 Apr 24 | Eben Tessari | Restricted Share Unit Class A Common Share | Option exercise | Dispose M | No | No | 0 | 2,726 | 0.00 | 9,573 |
8 Apr 24 | Ross Moat | Class A Common Share | Payment of exercise | Dispose F | No | No | 17.9 | 1,353 | 24.22 k | 16,276 |
8 Apr 24 | Ross Moat | Class A Common Share | Option exercise | Acquire M | No | No | 0 | 2,477 | 0.00 | 17,629 |
8 Apr 24 | Ross Moat | Restricted Share Unit Class A Common Share | Option exercise | Dispose M | No | No | 0 | 2,477 | 0.00 | 9,318 |
8 Apr 24 | Megna Michael R | Class A Common Share | Payment of exercise | Dispose F | No | No | 17.9 | 1,666 | 29.82 k | 21,328 |
8 Apr 24 | Megna Michael R | Class A Common Share | Option exercise | Acquire M | No | No | 0 | 3,932 | 0.00 | 22,994 |
8 Apr 24 | Megna Michael R | Restricted Share Unit Class A Common Share | Option exercise | Dispose M | No | No | 0 | 3,932 | 0.00 | 13,190 |
8 Apr 24 | Mark Ragosa | Class A Common Share | Payment of exercise | Dispose F | No | No | 17.9 | 791 | 14.16 k | 18,771 |
News
Kiniksa Pharmaceuticals Q1 2024 GAAP EPS $(0.25) Misses $(0.14) Estimate, Sales $79.858M Beat $78.460M Estimate
23 Apr 24
Earnings Scheduled For April 23, 2024
23 Apr 24
Kiniksa Expects 2024 ARCALYST Net Product Revenue Of Between $360M-$380M; That Its Cash, Cash Equivalents, And Short-Term Investments Will Fund Its Current Operating Plan Into At Least 2027
28 Feb 24
Kiniksa Pharmaceuticals Q4 EPS $0.35 Beats $(0.14) Estimate, Sales $83.39M Beat $72.02M Estimate
28 Feb 24
Earnings Scheduled For February 28, 2024
28 Feb 24
Press releases
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23 Apr 24
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
16 Apr 24
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
2 Apr 24
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28 Feb 24
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
21 Feb 24